米国のMRD検査施設

米国のMRD (微小残存病変) 検査の市場規模は、2024年から2030年の予測期間中にCAGR 14.18%で推移し、2030年には16億6,750万米ドルの規模に達すると予測されています。

米国の検査施設は、2023年に世界のMRD検査施設全体の39.53％のシェアを示しています。

MRD検査は、特定の癌、特に白血病とリンパ腫の追跡において重要な役割を果たしています。米国では多くの検査施設や医療機関がMRD検査サービスを提供しています。この種の検査は、腫瘍の診断と治療モニタリングに不可欠な要素へと発展してきました。残存癌細胞の高感度検出など、その革新的な能力は、次世代シーケンシング (NGS)、デジタルPCR、フローサイトメトリーなどの先端技術の採用を後押ししています。

米国における施設の地理的分布に関する洞察

• 米国内のMRD検査施設の分布は、アクセスと利用における地域格差を浮き彫りにしています。カリフォルニア、ニューヨーク、テキサスなどの州は、強固なヘルスケアインフラと高い癌罹患率を背景に、MRD検査件数をリードしています。
• 逆に、カンザス州やネバダ州のように人口が少ない州では、検査件数は少ないもの、1人当たりの利用率は競争力を維持しています。CAPおよびCLIA認定を受けた認定施設が主流を占めており、高品質の検査と厳格な規制基準の遵守を保証しています。

当レポートでは、米国の約200のMRD (微小残存病変) 検査施設の市場を調査し、米国におけるMRD検査の概要、MRD検査施設のプロファイル、市場規模の推移・予測、技術の展望、市場影響因子の分析などをまとめています。

本調査では、米国の約200の検査施設のプロファイリングに焦点を当て、戦略的計画、市場分析、ベンチマーキングに貴重な洞察を提供します。ステークホルダーは経営指標を比較し、十分なサービスを受けていない地域を特定し、提携の機会を探ることができます。詳細な検査データは、臨床ワークフローの最適化、先進技術の採用、業界標準との整合に役立ちます。また、規制要件の遵守を支援し、資金調達のアドボカシーを強化します。

調査カテゴリー：

• MRD検査施設
• MRD検査病院
• MRD検査会社
• MRD検査センター
• MRD検査件数
• MRD市場

目次

米国のMRD検査の概要

米国のMRD検査市場の規模・予測

米国のMRD検査市場の技術情勢

米国のMRD検査市場のエンドユーザー統計

米国のMRD検査市場：市場力学：主な促進要因

米国のMRD検査市場：市場力学：主な課題

米国のMRD検査市場：市場力学：市場機会

米国のMRD検査施設のプロファイル

Market Analysis of MRD Testing Facility in the U.S.

BIS research is engaged in a study focusing on U.S. MRD ((Minimal Residual Disease) Testing Facilities Market. The report is focused on an overview of MRD testing in U.S., profiles of MRD testing facilities, market size, 2020-2030, technology landscape and key dynamics of the market.

MRD testing plays a crucial role in tracking certain cancers, particularly leukaemia and lymphoma. Many laboratories and medical institutions across the U.S. provide MRD testing services. This type of testing has evolved into an indispensable component of oncology diagnostics and treatment monitoring. Its transformative capabilities, including high sensitivity in detecting residual cancer cells, have propelled the adoption of advanced technologies such as Next-Generation Sequencing (NGS), digital PCR, and flow cytometry.

Objective of the Study

This study aims to systematically profile approximately 200 Minimal Residual Disease (MRD) Testing Facilities across the United States, encompassing the following categories:

• MRD Testing Laboratories
• MRD Testing Hospitals
• MRD Testing Companies
• MRD Testing Centers
• MRD Testing Volume
• MRD Market

The study is focused on profiling about 200 testing facilities in U.S. providing valuable insights for strategic planning, market analysis, and benchmarking. Stakeholders can compare operational metrics, identify underserved regions, and explore partnership opportunities. The detailed test data helps optimize clinical workflows, adopt advanced technologies, and align with industry standards. It also supports compliance with regulatory requirements and enhances funding advocacy. Overall, the report is a comprehensive resource for driving innovation and competitiveness in the MRD testing landscape.

Insights on Geographical Distribution of Facilities in U.S.

Geographical Distribution and Facility Insights

• The distribution of MRD testing facilities across the U.S. highlights regional disparities in access and utilization. States like California, New York, and Texas lead in MRD test volumes, driven by robust healthcare infrastructure and a high incidence of cancer.
• Conversely, states with smaller populations, such as Kansas and Nevada, exhibit lower test volumes but maintain competitive per capita utilization rates. Accredited facilities with CAP and CLIA certifications dominate the landscape, ensuring high-quality testing and compliance with stringent regulatory standards.

The current study also highlights the number of diagnostic laboratories in US testing MRD. California reported the highest number of MRD testing facilities in 2022 with a test volume of 156,658 and test per Capita 401. New York and Texas also followed California in testing facilities. However, Missouri and Utah reported the lowest test volume i.e. 2,554 and 2,720 respectively.

Moreover, companies are also carrying out MRD testing at a higher volume. For instance, Adaptive Biotechnologies carried out 36,871 NGS-based MRD clonoSEQ tests in 2022 as compared to 22,516 NGS-based MRD clonoSEQ tests in 2021. Company reported 51% Y-o-Y growth. Hence, this rising volume of MRD testing is anticipated to boost the overall market growth.

Market Size Estimates, 2020-2030

The U.S. MRD testing market is poised to reach $1,667.5 million by 2030, with a CAGR of 14.18% during the forecast period 2024 and 2030. U.S. testing facilities market accounted for a substantial 39.53% share in 2023 in the overall global MRD testing facilities. In the U.S., several facilities offer MRD testing, with factors such as technology used, test accuracy, and clinical expertise driving the choice of where to get tested.

Report also focuses on the market dynamics, technology landscape and challenges of the market

• The robust growth of the MRD testing market in the U.S. can be attributed to a confluence of factors, including increasing cancer incidence, rising demand for personalized treatment, and rapid advancements in molecular diagnostics. According to the American Cancer Society, leukemia accounted for 13% of adolescent cancer diagnoses in 2022, while myeloma diagnoses exceeded 34,000 cases in the same year. Furthermore, based on the findings of the study. hospitals and specialty clinics dominate the end-user segment, comprising 44.01% of the market in 2023. This sector's strategic integration of MRD testing into oncology services reflects the growing emphasis on personalized medicine. Research institutions and diagnostic laboratories also contribute significantly, with anticipated CAGRs of 14.1% and 13.3%, respectively, during the forecast period. These segments highlight the expanding role of MRD testing in clinical trials and routine diagnostics.

Conclusion

The increasing adoption of these advanced technologies is revolutionizing MRD testing, making it more precise, accessible, and essential for shaping cancer treatment approaches. As the field evolves, there is a growing emphasis on developing personalized treatment plans informed by the in-depth genetic data obtained through MRD testing.

The U.S. MRD testing market is at the forefront of oncology diagnostics, characterized by continuous innovation, strategic collaborations, and a growing emphasis on personalized medicine. While challenges such as cost barriers and sensitivity limitations persist, advancements in companion diagnostics, Medicare coverage expansion, and clinical trials offer promising solutions. By addressing these hurdles and leveraging emerging opportunities, the MRD testing market is well-positioned to enhance cancer care and improve patient outcomes in the years to come.

Table of Contents

Overview of MRD Testing in the U.S.

U.S. MRD Testing Market Size, 2020-2030

U.S. MRD Testing Market Technology Landscape

U.S. MRD Testing Market End-User Stats

U.S. MRD Testing Market Dynamics: Key Drivers

U.S. MRD Testing Market Dynamics: Key Challenges

U.S. MRD Testing Market Dynamics: Market Opportunities

U.S. MRD Testing Facility Profiles